Microbot Medical Surges 19% on FDA Clearance Breakthrough: Is This the Dawn of a New Era in Robotic Surgery?

Summary
• Microbot Medical (MBOT) rockets 19.12% to $4.36, hitting an intraday high of $4.52 after FDA 510(k) clearance for its LIBERTY® robotic system.
• CEO Harel Gadot to present live at H.C. Wainwright conference on September 9, 2025, at 9 AM ET.
• Company targets $2.5 million annual U.S. peripheral vascular procedures with its first single-use, remotely operated robotic system.

Microbot Medical’s stock has erupted on the heels of a landmark regulatory milestone, with the FDA granting clearance for its LIBERTY® Endovascular Robotic System. The surge, which saw the stock trade as high as $4.52 and as low as $3.48, underscores investor enthusiasm for the company’s commercialization roadmap. With a 52-week high of $4.62 just within reach, the market is betting on the transformative potential of this first-of-its-kind robotic solution.

FDA Clearance Ignites Bullish Sentiment
Microbot Medical’s 19.12% intraday surge is directly attributable to the FDA’s 510(k) clearance for its LIBERTY® Endovascular Robotic System, a first-in-class single-use, remotely operated platform for peripheral endovascular procedures. The clearance removes a critical regulatory barrier, enabling the company to commercialize its technology in the U.S. by Q4 2025. CEO Harel Gadot emphasized that this achievement validates the company’s mission to democratize robotic surgery while reducing costs and radiation exposure for physicians. The pivotal study’s 100% success rate in robotic navigation and 92% reduction in radiation exposure further bolster investor confidence, positioning LIBERTY® as a disruptive force in a $2.5 million annual U.S. market.

Medical Device Sector Mixed as MBOT Defies Peers
While Microbot Medical’s stock surged, the broader medical device sector showed mixed performance. Medtronic (MDT), the sector leader, declined 0.54% intraday, reflecting sector-wide caution. However, MBOT’s rally is driven by its unique regulatory milestone rather than sector-wide trends. The FDA clearance for LIBERTY® highlights the company’s differentiated value proposition in robotic surgery, a niche with high growth potential despite broader sector volatility.

Options Playbook: Leveraging Volatility in a Bullish Setup
• MACD: 0.227 (bullish divergence from signal line 0.262)
• RSI: 61.18 (neutral, avoiding overbought/oversold extremes)
• Bollinger Bands: Price at $4.36, above middle band ($3.47), suggesting short-term strength.
• 200D MA: $2.13 (far below current price, indicating long-term bullish trend).

Microbot Medical’s technicals align with a continuation of its bullish breakout. Key support levels at $2.67 (lower Bollinger Band) and $2.46 (200D MA) remain distant, while resistance at $4.62 (52W high) looms. The 61.18 RSI reading suggests the stock is not overbought, leaving room for further gains. For leveraged exposure, options with high gamma and moderate delta offer asymmetric potential.

Top Option 1: MBOT20251017C5
• Strike: $5.00, Expiration: 2025-10-17, Delta: 0.45, IV: 120.45%, Theta: -0.0102, Gamma: 0.2266, Turnover: $129,353
• IV (120.45%): High volatility implies significant price swings.
• Delta (0.45): Moderate sensitivity to price changes.
• Gamma (0.2266): High sensitivity to price movement, ideal for volatile setups.
• Payoff at 5% Upside (ST = $4.57): Max(0, $4.57 - $5.00) = $0 (out of the money).
• Why it stands out: High gamma and IV make this call option responsive to continued upside, though it’s slightly out of the money.

Top Option 2: MBOT20260116C5
• Strike: $5.00, Expiration: 2026-01-16, Delta: 0.55, IV: 105.24%, Theta: -0.00465, Gamma: 0.1431, Turnover: $267,246
• IV (105.24%): Reasonable volatility for a longer-dated contract.
• Delta (0.55): Strong sensitivity to price changes.
• Gamma (0.1431): Moderate sensitivity, balancing risk and reward.
• Payoff at 5% Upside (ST = $4.57): Max(0, $4.57 - $5.00) = $0 (out of the money).
• Why it stands out: Higher liquidity and moderate IV make this a safer bet for a bullish stance with time decay working in its favor.

Trading Insight: Aggressive bulls may consider MBOT20260116C5 into a breakout above $4.62, leveraging its moderate delta and high liquidity for a long-term play.

Backtest Microbot Medical Stock Performance
Below is an interactive event-study panel that visualises the performance of Microbot Medical (MBOT.O) following every ≥19 % single-day price jump since 1 Jan 2022.Key take-aways (concise):• Six qualifying surge events were found over the sample window. • Average 1-day, 5-day and 30-day post-event returns were –8.7 %, –21.1 % and –10.7 % respectively, all under-performing the benchmark. • Statistical tests flag the first week’s drawdown as significantly negative; performance begins to stabilise only after ~10 trading days. • Win-rate never exceeds 33 % at any horizon ≤30 days, indicating limited follow-through upside after such extreme single-day moves.Assumptions & methodology clarification:1. “Intraday surge” defined as close-to-close daily return ≥19 %; this is the most widely available and auditable data field. 2. Backtest window starts 2022-01-01 and ends 2025-09-08 (today). 3. Benchmark is the stock’s own unconditional return path over the same period. 4. No transaction costs or slippage included; results shown are raw price performance. Feel free to click into the module to explore event-level details, daily P/L curves and significance diagnostics.

Breakout or Bubble? The Clock is Ticking for Microbot Medical
Microbot Medical’s 19.12% surge on FDA clearance is a watershed moment, but sustainability hinges on execution. The stock’s technicals—bullish MACD, neutral RSI, and a 52W high within reach—signal a strong short-to-midterm outlook. However, the sector leader Medtronic (MDT) declined 0.54%, highlighting broader market caution. Investors should monitor the $4.62 52W high as a critical resistance level and watch for follow-through volume. For now, the options market is pricing in volatility, with contracts like MBOT20260116C5 offering a balanced leveraged play. Action Step: Target a breakout above $4.62 or a breakdown below $3.48 (intraday low) to confirm the trade’s direction.